Navigation Links
Two Year Study Confirms SUPPRELIN(R) LA Implant Maintains Profound Suppression of Hormones in Children With Premature Onset Puberty
Date:5/5/2008

LEXINGTON, Mass., May 5 /PRNewswire-FirstCall/ -- Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced positive results of the ongoing Phase III extension study of SUPPRELIN(R) LA (histrelin acetate), the only once-yearly subcutaneous implant for the treatment of central precocious puberty or early onset puberty, at the Lawson Wilkins Pediatric Endocrine Society (LWPES) Annual Meeting. This study evaluated the two-year safety and efficacy of SUPPRELIN LA in children who received a second implant following an initial year of therapy. The study found that SUPPRELIN LA demonstrated continued profound hormone suppression with no escapes (breakthrough of hormones) and led to continued decreases in rates of growth, skeletal maturation and body mass index at 24 months compared to 12 months.

"This study confirms that SUPPRELIN LA maintains remarkable suppression of peak hormone and sex steroid levels for two years in children with central precocious puberty and that the removal of the first implant and insertion of the second does not influence efficacy," said Gad Kletter, MD, Head of Pediatric Endocrinology, Swedish Medical Center, Seattle, WA. "While the frequent dosing of traditional injections may lead to issues with long-term compliance, SUPPRELIN LA offers patients, families and physicians a truly sustained treatment option that only requires action once a year."

"Central precocious puberty can be a devastating condition physically, psychologically and socially and is extremely difficult to manage," stated Bobby Sandage, Jr., Ph.D., Executive Vice President, Research and Development and Chief Scientific Officer, Indevus Pharmaceuticals. "We are encouraged by these recent findings and hope they provide an added level of comfo
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 Plant disease ... this summer at the Annual Meeting of The American ... to be released online now at APSnet.org/meet . ... for the meeting, to be held August 1-5, 2015 ... Special Sessions, Field Trips, Workshops, and committee meetings, all ...
(Date:3/5/2015)... 2015 Bi-Biomics today announced a ... stain additive. The improvement in histological quality provided ... present in all daughter cells. , After processing ... was analyzed at 1000-1600x using light microscopy. ... in all daughter cells displayed predominant binary features ...
(Date:3/5/2015)... SAN DIEGO and TORONTO ... APTO, TSX: APS), a clinical-stage company developing new therapeutics ... cancer, today announced that William G. Rice , ... at the upcoming 27th Annual ROTH Conference on Tuesday, ... the The Ritz Carlton, Laguna Niguel, CA. ...
(Date:3/5/2015)... Mar. 05, 2015 Research and Markets ... "Mature Biotech Outlook 2015: New Therapy Ventures Pave ... All biotech companies - Gilead (GILD), ... past year, have given a positive return and hence ... been able to select therapy/niche indication where the high ...
Breaking Biology Technology:American Phytopathological Society Announces Annual Meeting Daily Schedule 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3
... to a biotech company (it is priority #1, #2, and ... sense) companies are continually faced with the challenge of raising ... article will focus on venture capital financing results for 2005. ... from Burrill and Company's data. Burrill's perspective is more towards ...
... before I get all lathered up about the latest outrages ... recognize completely that the majority of top executives are honest ... to success. And that the CEO's I will be talking ... are people who work the system to their great benefit ...
... statewide, is holding information sessions for parents until the end ... ,Children enrolled in the academy are lent a computer, monitor, ... home with a parent or other responsible adult and correspond ... Since it's a public school, there is no tuition. , ...
Cached Biology Technology:U.S. VC funding flat in 2005 while life science funding grows 2U.S. VC funding flat in 2005 while life science funding grows 3U.S. VC funding flat in 2005 while life science funding grows 4What color is your CEO's parachute? 2What color is your CEO's parachute? 3What color is your CEO's parachute? 4
(Date:2/5/2015)... , January 28, 2015 New ... Size And Segment Forecasts To 2020 has Been Added ... camera market is expected to reach USD 5.10 billion ... View Research, Inc. IR cameras help identify the site ... expected to witness surging demand in medical imaging applications. ...
(Date:2/5/2015)... 3, 2015 Despite a lack of ... such as consumer electronics, automotive, storage and telecommunication ... technology (SMT) screen printers. Innovations in electronics and ... push the adoption curve up. Meanwhile, sale volumes ... glue dispensers are indispensable in the production of ...
(Date:1/22/2015)... , Jan. 13, 2015  Today, FreeWavz ( www.FreeWavz.com ... its crowdfunding campaign on Fundable, https://www.fundable.com/freewavz . ... of production capacity to meet customer demand. ... - http://photos.prnewswire.com/prnh/20150113/168790 Invented ...
Breaking Biology News(10 mins):IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... therapy often harms healthy tissue as it tries to kill ... Department of Biomedical Engineering is developing a new way to ... surrounding tissue. His innovative method, soon to be ... kill the tumor cells but leaves surrounding healthy tissue intact. ...
... a leading cause of mortality worldwide, accounting for more than ... expected to exceed 12 million. The ESMO Congress provides a ... the treatment of cancer Congress Program Highlights ... potentially practice changing, Promising new drugs to treat ovarian, skin, ...
... Under the microscope, the bacteria start dividing normally, two ... then individual cells begin "popping," like circus balloons being struck ... bioengineers who captured it on video, turns out to be ... considered by scientists creating living, synthetic circuits out of bacteria. ...
Cached Biology News:A 'magnetic' solution to identify and kill tumors 235th ESMO Congress media alert 235th ESMO Congress media alert 3Popping cells surprise living circuits creators 2Popping cells surprise living circuits creators 3
Glucagon-like peptide-1 (GLP-1 (1-36) amide)...
Complement factor B (human)...
... NH2-terminal kinase) signal transduction cascade is ... pathways in mammals. JNK pathway activation ... is associated with the nuclear accumulation ... in the immune response, cellular proliferation, ...
... near- and far-infrared range FT-IR spectrometers give ... their class. Yet all this comes at ... throughput: Having a larger and faster ... other conventional FT-IRs provides 300%,larger solid angle ...
Biology Products: